Ming-Hsien Tsai Selected Research

protein phosphatase 5

12/2018	Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
1/2018	Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
1/2018	Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
10/2017	Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
1/2017	Protein phosphatase 5 promotes hepatocarcinogenesis through interaction with AMP-activated protein kinase.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ming-Hsien Tsai Research Topics

Disease

33	Neoplasms (Cancer) 10/2022 - 05/2007
11	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 02/2008
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 12/2016
7	Carcinogenesis 03/2021 - 07/2007
6	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 07/2016
5	Inflammation (Inflammations) 04/2022 - 12/2011
5	Chronic Renal Insufficiency 11/2021 - 03/2016
5	Lung Neoplasms (Lung Cancer) 01/2018 - 05/2007
4	Infections 01/2022 - 10/2015
4	Pneumonia (Pneumonitis) 07/2019 - 09/2013
3	Squamous Cell Carcinoma of Head and Neck 10/2022 - 01/2018
3	Hemorrhage 10/2021 - 01/2012
3	Nasopharyngeal Carcinoma 10/2021 - 04/2020
3	Breast Neoplasms (Breast Cancer) 10/2018 - 09/2008
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 10/2017
3	Lung Diseases (Lung Disease) 01/2017 - 05/2007
2	Head and Neck Neoplasms (Head and Neck Cancer) 10/2022 - 01/2018
2	Vascular Diseases (Vascular Disease) 01/2022 - 05/2021
2	Anemia 10/2021 - 03/2016
2	Hypertension (High Blood Pressure) 01/2021 - 07/2019
2	Hyperlipidemias (Hyperlipidemia) 01/2021 - 01/2018
2	Adenoma (Adenomas) 07/2020 - 07/2016
2	Wounds and Injuries (Trauma) 01/2020 - 03/2019
2	Hypoalbuminemia 01/2020 - 01/2018
2	Cholangiocarcinoma 12/2018 - 10/2018
2	Hypokalemia 01/2018 - 09/2015
2	Adenocarcinoma of Lung 01/2017 - 02/2009
2	Cytokine Release Syndrome 01/2016 - 01/2016
2	Melanoma (Melanoma, Malignant) 11/2015 - 09/2010
2	Endocarditis 10/2015 - 04/2015
2	Major Depressive Disorder (Major Depressive Disorders) 04/2011 - 04/2010
1	Tinnitus 01/2022
1	Sensorineural Hearing Loss 01/2022
1	Disease Progression 01/2022
1	Dementia (Dementias) 11/2021
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 10/2021
1	Ischemic Stroke 10/2021
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 10/2021
1	Hyperglycemia 10/2021
1	Rhinosinusitis 01/2021
1	Nasal Polyps (Nasal Polyp) 01/2021
1	Fibromyalgia (Fibrositis) 12/2020
1	Hyperalgesia 12/2020

Drug/Important Bio-Agent (IBA)

6	Pharmaceutical PreparationsIBA 01/2019 - 04/2016
5	Proteins (Proteins, Gene)FDA Link 02/2021 - 09/2010
5	protein phosphatase 5IBA 12/2018 - 01/2017
4	Particulate MatterIBA 01/2022 - 02/2019
4	CytokinesIBA 01/2021 - 01/2016
4	tissue-factor-pathway inhibitor 2 (PP5)IBA 12/2018 - 01/2017
4	MicellesIBA 01/2018 - 09/2008
4	ArsenicIBA 06/2012 - 01/2007
3	LipidsIBA 01/2022 - 01/2018
3	PotassiumIBA 07/2020 - 01/2018
3	Hemoglobins (Hemoglobin)IBA 01/2020 - 03/2016
3	AMP-Activated Protein KinasesIBA 01/2018 - 10/2017
3	p120 GTPase Activating ProteinIBA 10/2017 - 05/2016
3	Non-Receptor Type 1 Protein Tyrosine PhosphataseIBA 10/2017 - 05/2016
3	Zinc Oxide FDA Link 01/2017 - 09/2013
3	Benzo(a)pyreneIBA 07/2016 - 07/2007
3	Sorafenib (BAY 43-9006)FDA Link 05/2016 - 02/2016
3	SmokeIBA 06/2012 - 02/2008
2	Polycyclic Aromatic Hydrocarbons (Polynuclear Aromatic Hydrocarbons)IBA 01/2022 - 01/2017
2	Angiotensin Receptor AntagonistsIBA 11/2021 - 01/2021
2	Biological ProductsIBA 12/2020 - 07/2016
2	Serum AlbuminIBA 01/2020 - 01/2018
2	CarcinogensIBA 01/2020 - 07/2016
2	Threonine (L-Threonine)FDA Link 12/2018 - 07/2016
2	palbociclibIBA 10/2018 - 01/2017
2	oxidized low density lipoproteinIBA 01/2018 - 01/2018
2	ErbB Receptors (EGF Receptor)IBA 01/2018 - 07/2016
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2018 - 11/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016 - 12/2011
2	AcidsIBA 09/2015 - 10/2014
2	IronIBA 09/2013 - 01/2012
1	Cetuximab (Erbitux)FDA Link 10/2022
1	omega-Chloroacetophenone (Mace)IBA 01/2022
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2021
1	Metformin (Glucophage)FDA LinkGeneric 10/2021
1	Docetaxel (Taxotere)FDA Link 03/2021
1	TOR Serine-Threonine KinasesIBA 03/2021
1	Trypan Blue FDA Link 03/2021
1	MTOR InhibitorsIBA 03/2021
1	Uremic ToxinsIBA 02/2021
1	Losartan (Cozaar)FDA LinkGeneric 01/2021
1	Valsartan (Vals)FDA Link 01/2021
1	MagnesiumIBA 01/2021
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 12/2020

Therapy/Procedure

8	Therapeutics 01/2019 - 11/2015
4	Drug Therapy (Chemotherapy) 07/2017 - 09/2008
4	Renal Dialysis (Hemodialysis) 12/2016 - 02/2015
3	Radiotherapy 01/2020 - 01/2018
3	Photochemotherapy (Photodynamic Therapy) 01/2018 - 09/2008
2	Aftercare (After-Treatment) 01/2022 - 10/2021
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 10/2021 - 04/2020
2	Free Tissue Flaps 01/2020 - 01/2018
2	Catheters 03/2019 - 04/2015
2	Precision Medicine 01/2019 - 01/2017
1	Re-Irradiation 10/2022
1	Fecal Microbiota Transplantation 04/2022
1	Molecular Targeted Therapy 03/2021